Juvenile Macular Degeneration Treatment Market Report 2026

The juvenile macular degeneration treatment market size has grown strongly in recent years. It will grow from $1.39 billion in 2025 to $1.5 billion in 2026 at a compound annual growth rate (CAGR) of 7.9%. The growth in the historic period can be attributed to limited treatment options for juvenile macular degeneration, increasing awareness of inherited retinal disorders, advancement in retinal imaging technologies, growth in ophthalmology specialty care, rising diagnosis rates of stargardt disease.

The juvenile macular degeneration treatment market size is expected to see strong growth in the next few years. It will grow to $2.01 billion in 2030 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to advancements in gene and stem cell research, increasing investment in rare disease therapeutics, growing focus on early intervention in pediatric eye disorders, expansion of clinical research pipelines, improving access to specialized ophthalmic care. Major trends in the forecast period include rising focus on genetic eye disorder management, growing adoption of gene and stem cell therapies, increasing use of vision preservation and assistive devices, expansion of clinical trials for rare retinal diseases, improved patient support and low-vision rehabilitation programs.

The rising prevalence of retinal disorders is anticipated to drive the growth of the juvenile macular degeneration treatment market in the coming years. Retinal disorders encompass a range of conditions that impact the retina, the light-sensitive layer at the back of the eye, resulting in vision impairment or loss. The incidence of retinal disorders is increasing due to the growing prevalence of diabetes, which can lead to conditions like diabetic retinopathy that progressively damage the retina. Treatments for juvenile macular degeneration support the management of retinal disorders by preserving vision through early intervention, making them particularly important for young patients. For example, in November 2024, a report published by Retina Australia, an Australia-based non-profit organization, estimated that around 19,000 individuals in Australia, or approximately 1 in 1,380 people, are living with an inherited retinal disease (IRD). Additionally, according to the National Eye Institute, a US-based health institute, the number of Americans with advanced age-related macular degeneration (AMD) is projected to rise from 2.1 million currently to 3.7 million by 2030. Thus, the growing prevalence of retinal disorders is fueling the expansion of the juvenile macular degeneration treatment market.

Major companies operating in the juvenile macular degeneration treatment market are concentrating on developing innovative solutions, such as dual adeno-associated viral (AAV) vectors, to improve gene therapy delivery and enhance treatment outcomes for patients with juvenile macular degeneration. A dual adeno-associated viral (AAV) vector is a gene therapy strategy that employs two AAV vectors to deliver large therapeutic genes that exceed the capacity of a single AAV. For example, in March 2025, SpliceBio, a Spain-based biotechnology company, announced the first patient dosing in its Phase 1/2 ASTRA study for SB-007, a dual AAV vector gene therapy designed to restore full-length ABCA4 protein expression. The therapy aims to offer a potential treatment for juvenile macular degeneration (Stargardt disease), an inherited retinal disorder with no approved therapies, by targeting all patients regardless of their mutations. This milestone represents a significant advancement toward developing effective gene therapies for rare retinal disorders.

In July 2023, Astellas Pharma Inc., a Japan-based pharmaceutical company, acquired IVERIC Bio Inc. for an undisclosed amount. Through this acquisition, Astellas aims to enhance its ophthalmology portfolio, accelerate the development of innovative therapies for retinal diseases, and expand its capabilities in gene therapy and complement inhibition, particularly for conditions such as Stargardt disease and geographic atrophy. IVERIC Bio Inc. is a US-based company focused on developing treatments for juvenile macular degeneration, specifically Stargardt disease.

Major companies operating in the juvenile macular degeneration treatment market are Alkeus Pharmaceuticals Inc., MeiraGTx Holdings plc, Ocugen Inc., ProQR Therapeutics N.V., Applied Genetic Technologies Corporation, Lineage Cell Therapeutics Inc., jCyte Inc., Nanoscope Therapeutics Inc., Editas Medicine Inc., Beam Therapeutics Inc., ReNeuron Group plc, Astellas Institute for Regenerative Medicine, Kubota Vision Inc., Ionis Pharmaceuticals Inc., Atsena Therapeutics Inc., Vedere Bio Inc., GenSight Biologics S.A., ViGeneron GmbH, Sanofi Gene Therapy, Neurotech Pharmaceuticals Inc.

North America was the largest region in the juvenile macular degeneration treatment market in 2025. The regions covered in the juvenile macular degeneration treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the juvenile macular degeneration treatment market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have moderately impacted the juvenile macular degeneration treatment market by increasing costs of imported ophthalmic devices, advanced surgical equipment, and gene therapy-related materials. Treatment segments such as gene therapy, stem cell therapy, and specialized retinal devices are most affected, particularly in north america and europe due to reliance on cross-border innovation and manufacturing. Hospitals and ambulatory surgical centres face higher procurement costs, potentially affecting treatment affordability. However, tariffs have encouraged localized manufacturing, regional clinical research collaborations, and long-term strengthening of domestic ophthalmic technology supply chains.

The juvenile macular degeneration treatment market research report is one of a series of new reports that provides juvenile macular degeneration treatment market statistics, including juvenile macular degeneration treatment industry global market size, regional shares, competitors with a juvenile macular degeneration treatment market share, detailed juvenile macular degeneration treatment market segments, market trends and opportunities, and any further data you may need to thrive in the juvenile macular degeneration treatment industry. This juvenile macular degeneration treatment market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Juvenile macular degeneration (Stargardt disease) treatment involves various approaches aimed at managing vision loss and enhancing the quality of life for individuals affected by this inherited eye disorder. It results from genetic mutations that damage the macula, the central part of the retina, causing gradual vision loss and difficulties with tasks such as reading and recognizing faces.

The primary forms of juvenile macular degeneration treatment include wet age-related macular degeneration and dry age-related macular degeneration. Wet age-related macular degeneration occurs when abnormal blood vessels develop beneath the retina, causing fluid or blood leakage and rapid loss of central vision. Treatments for juvenile macular degeneration include devices, medications, and surgical interventions. These treatments are used for vision preservation, disease management, symptom relief, preventive care, and clinical trials, and they are provided through various channels such as hospitals, ambulatory surgical centers, and other healthcare facilities.

The juvenile macular degeneration treatment market consists of revenues earned by entities by providing services such as vision therapy, low vision rehabilitation, genetic counseling, nutritional counseling, and psychological support for vision loss management. The market value includes the value of related goods sold by the service provider or included within the service offering. The juvenile macular degeneration (JMD) treatment market also includes sales of prescription eyewear, low vision aids, braille displays, specialty lighting devices, and dietary supplements for eye health. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.